Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting

Core Insights - Xilio Therapeutics, Inc. is set to present a poster at the American Association for Cancer Research (AACR) Annual Meeting, focusing on their masked immuno-oncology therapy, XTX601, which targets Claudin 18.2 [1] Company Overview - Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing masked immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects associated with current therapies [2]